1,3-Benzoxazol-4-amine → HCID 136041746, Verbindung
Reaktionsgleichung
[N:1]1([C:7]2[N:8]=[C:9]([CH2:14][C:15]([O-:17])=O)[NH:10][C:11](=[O:13])[CH:12]=2)[CH2:6][CH2:5][O:4][CH2:3][CH2:2]1.[Na+].[O:19]1[C:23]2=[CH:24][CH:25]=[CH:26][C:27]([NH2:28])=[C:22]2[N:21]=[CH:20]1>>[O:19]1[C:23]2[CH:24]=[CH:25][CH:26]=[C:27]([NH:28][C:15](=[O:17])[CH2:14][C:9]3[NH:10][C:11](=[O:13])[CH:12]=[C:7]([N:1]4[CH2:2][CH2:3][O:4][CH2:5][CH2:6]4)[N:8]=3)[C:22]=2[N:21]=[CH:20]1Komponenten
3
Versuchsvorschrift
The product is prepared according to the procedure described in Example 5, using 260 mg of sodium [4-(morpholin-4-yl)-6-oxo-1,6-dihydropyrimidin-2-yl]acetate and 268 mg of 1,3-benzoxazol-4-amine in place of the 2,4-difluoroaniline. 193 mg of N-(1,3-benzoxazol-4-yl)-2-[4-(morpholin-4-yl)-6-oxo-1,6-dihydropyrimidin-2-yl]acetamide are obtained in the form of an ecru solid, the characteristics of which are the following:
Aufarbeitung
- customThe product is prepared